Results 101 to 110 of about 385 (131)

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Background: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients’ health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. Objectives: This study sought to determine the effect of aficamten
Michael Nassif, Pablo García-Pavía
exaly   +3 more sources

Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten

Current Problems in Cardiology
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), which can lead to left ventricular outflow tract (LVOT) obstruction. Traditional treatments often provide limited symptom relief and may not adequately reduce the LVOT gradient.
Adetola Emmanuel Babalola, Emmanuel Kokori, Nicholas Aderinto   +2 more
exaly   +3 more sources

Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy: Unlocking New Horizons?

European Journal of Heart Failure
N ...
Rossi, Maddalena, Fabris, Enrico, Sinagra, Gianfranco   +2 more
openaire   +3 more sources

Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy

The Medical Letter on Drugs and Therapeutics
Aficamten (Myqorzo – Cytokinetics), an oral cardiac myosin inhibitor, has been approved by the FDA to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the second cardiac myosin inhibitor to be approved in the US for this indication; mavacamten (Camzyos) was approved in 2022.
openaire   +1 more source

Synthesis of Aficamten

Synfacts, 2021
openaire   +1 more source

Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials

The American Journal of Cardiology
Myosin inhibitors represent a novel therapeutic class for hypertrophic cardiomyopathy (HCM). While both mavacamten and aficamten have been evaluated in randomized trials, comparative evidence across the 2 agents remains limited. We performed a systematic review and meta-analysis of 8 randomized controlled trials of myosin inhibitors in HCM.
Md Fahim, Daoud Eldawud, Omar Wahadneh, Roy Wang, Asher Gorantla, Nischal Sharma, Peter Khouri, Louis Salciccioli   +7 more
openaire   +2 more sources

Aficamten for Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
Jorge, Pedreira-Bouzas, Álvaro, Pousada-Fonseca, Dolores, Fraga   +2 more
openaire   +3 more sources

Aficamten Monotherapy for Hypertrophic Cardiomyopathy

New England Journal of Medicine
Mapelli, Massimo, Willixhofer, Robin, Agostoni, Piergiuseppe   +2 more
openaire   +4 more sources

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants

JACC Basic To Translational Science, 2022
Fady Malik, Scott Solomon, Donghong Xu   +2 more
exaly